ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ACS Survey Finds Need for Cancer Education Among Hispanic Americans

August 2, 1985

FDA IND Approval Of New Cancer Drug Is First Based On Phase 1 Clinical Trials In Europe

December 5, 1986

U. S. Oncologists To Audit Another Bezwoda Trial.

November 10, 2000

NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

March 7, 2014

Dietary Interventions Reduce Breast Cancer Risk In Trials

May 27, 2005

Kington Named Acting NIH Director.

November 14, 2008